MedPath

Syndax's Revuforj Approved for Leukemia, Biosion Inks $940M Antibody Deal with Aclaris

• Syndax Pharmaceuticals' Revuforj (revumenib) received FDA approval as the first menin inhibitor for relapsed or refractory acute leukemia with specific genetic translocations. • Biosion granted Aclaris Therapeutics exclusive global rights to develop two antibodies, including BSI-045B (anti-TSLP) and BSI-502 (bispecific TSLP/IL4R), for up to $940 million. • Novartis expanded its radiopharma portfolio, licensing a somatostatin receptor 2 radiotherapeutic candidate from Ratio Therapeutics for cancer, potentially worth $745 million plus royalties.

Syndax Pharmaceuticals Inc. has secured FDA approval for Revuforj (revumenib), marking it as the first and only menin inhibitor available for patients with relapsed or refractory acute leukemia who have a lysine methyltransferase 2A (KMT2A) gene translocation. This approval, granted ahead of its December 26 PDUFA date, offers a new treatment option for both adult and pediatric patients (one year and older) facing this aggressive form of leukemia.
The FDA had previously recognized Revuforj as a breakthrough therapy and granted it fast track designation and priority review. The approval was facilitated through the FDA's Real Time Oncology Review program. Syndax Pharmaceuticals, based in Waltham, Mass., saw its shares rise following the announcement.

Aclaris Acquires Antibody Rights from Biosion in $940M Deal

In other news, Biosion Inc. has entered into an agreement with Aclaris Therapeutics Inc., granting Aclaris the global rights (excluding China) to develop two of its antibodies. The deal includes an upfront payment of over $40 million to Biosion, with the potential for an additional $900 million in regulatory and sales milestone payments.
The assets involved are BSI-045B, a high-affinity and high-potency anti-TSLP monoclonal antibody, and BSI-502, a bispecific antibody targeting both TSLP and IL4R. BSI-045B recently completed a phase IIa proof-of-concept study in patients with moderate to severe atopic dermatitis. Aclaris Therapeutics' stock experienced a significant boost following the announcement of the deal.

Novartis Expands Radiopharma Pipeline with Ratio Therapeutics Collaboration

Novartis AG continues to invest in radiopharmaceutical therapies, entering into an exclusive worldwide license and collaboration agreement with Ratio Therapeutics Inc. to develop a somatostatin receptor 2 (SSTR2) radiotherapeutic candidate for cancer. Ratio Therapeutics is eligible for upfront and potential milestone payments totaling $745 million, in addition to royalties. This deal marks another collaboration for Ratio, which has existing diagnostic-focused agreements with Lantheus Holdings Inc. and Merck & Co. Inc.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

GSK's Ovarian Cancer Drug Combination Shows Promise; Novo Nordisk's Obesity Drug Trial Disappoints

GSK's cancer drug combination achieved primary endpoints in ovarian cancer trials, marking a significant advancement in treatment options, though some secondary goals were unmet.
An Inter-American Court of Human Rights ruling highlighted the debate over El Salvador's abortion laws, citing a violation of a woman's rights in a 2013 case.

Outlook Therapeutics Faces Setback in AMD Trial; Other R&D Updates

Outlook Therapeutics' ONS-5010 failed to meet the noninferiority endpoint in a Phase III wet AMD trial, impacting company shares but BLA resubmission is still planned for early 2025.
The EMA revoked conditional marketing approval for Advanz Pharma's Ocaliva for primary biliary cholangitis (PBC) after a legal challenge failed.

FDA Approves BridgeBio's Attruby for Rare Heart Condition ATTR-CM

The FDA has approved BridgeBio's Attruby, offering a new treatment option for ATTR-CM, a rare heart condition, challenging Pfizer's previous dominance in this therapeutic area.
Research indicates that healthy breast cells may exhibit genetic changes similar to invasive breast cancer, raising concerns about diagnostic accuracy in breast cancer screening.

FDA Approves BridgeBio's Attruby for Rare Heart Condition, Challenging Pfizer's Vyndaqel

The FDA has approved BridgeBio's Attruby, a novel treatment for a rare heart condition, marking a significant advancement in cardiomyopathy treatments.
Studies suggest healthy breast cells may possess genetic traits leading to invasive breast cancer, prompting a re-examination of diagnostic norms.

Zepbound Demonstrates Superior Weight Loss Over Wegovy; FDA Actions Advance Lung Cancer and Psoriatic Arthritis Therapies

Eli Lilly's Zepbound showed a 47% greater relative weight loss compared to Novo Nordisk’s Wegovy in a head-to-head obesity study.
Merck's sacituzumab tirumotecan (Sac-TMT) received FDA Breakthrough Therapy designation for advanced NSCLC with EGFR mutations.

Mixed Results for Cancer and Neurological Drugs, Regulatory Scrutiny Intensifies for PBMs

Daiichi Sankyo and AstraZeneca's Dato-DXd failed to improve overall survival in the TROPION-Breast01 trial, despite earlier reports of delaying tumor progression in certain breast cancers.
Black Diamond Therapeutics reported a 42% tumor response rate for BDTX-1535 in EGFR-mutated non-small cell lung cancer resistant to Tagrisso.

Roche's Subcutaneous Tecentriq Approved; Gilead's HIV Shot Shows Promise

The FDA approved Roche's Tecentriq Hybreza, the first checkpoint inhibitor available as a subcutaneous injection, offering a faster administration time of about seven minutes.
Gilead's twice-yearly lenacapavir HIV shot reduced infection risk by 96% in a Phase 3 trial, leading to halted trial and plans for regulatory filings and a potential 2025 launch.

Roivant Acquires Mosliciguat from Bayer for Pulmonary Hypertension Treatment

Roivant Sciences has acquired mosliciguat, an experimental drug, from Bayer to develop as a treatment for pulmonary hypertension.
Mosliciguat targets specific types of pulmonary hypertension, addressing high blood pressure in lung arteries and heart damage.

AbbVie to Acquire Cerevel, Novartis' Fabhalta Approved, and Other Pharma Updates

AbbVie is set to acquire Cerevel Therapeutics for $8.7 billion, bolstering its neuroscience pipeline with candidates targeting schizophrenia, Parkinson's disease, and mood disorders.
The FDA has approved Novartis' Fabhalta (iptacopan), the first oral monotherapy for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.

Biotech Stock Roundup: Aldeyra Faces Setback, Annovis Bio Shows Positive Updates, and More

Aldeyra Therapeutics' stock plummeted after the FDA identified substantive review issues with its NDA for reproxalap for dry eye disease, potentially delaying approval.
Annovis Bio announced positive interim analysis from its Alzheimer's Disease study on buntanetap, indicating potential treatment effects after six weeks.

Reference News

[1]
Gender bias leaves women at risk in cardiology treatment guidelines - BioWorld
bioworld.com · Nov 19, 2024

Gender bias in cardiac treatment guidelines puts women at risk due to underrepresentation in clinical trials. Syndax Pha...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy